Further lack of association between the 5-HT 2A gene promoter polymorphism and susceptibility to eating disorders and a meta-analysis pertaining to anorexia nervosa SIR -Collier and colleagues reported an allelic association between the −1438G/A promoter polymorphism of the 5-HT 2A gene and anorexia nervosa (AN).
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Sorbi and colleagues 4 reported a strong positive association (P Ͻ0.0001) between the −1438A/G polymorphism and AN of the restricting type. However, our exploratory analyses for patients with AN of the restricting type vs controls revealed a nominal P-value Ͼ0.45 (data not shown). Due to the inconsistent findings of the different studies, we performed a metaanalysis as recommended by Baron. 8 For this purpose, a logistic regression using the original data was conducted. The model included a random effect to adjust for study of specific effects like ethnic diversity 9 because there was substantial deviation from study homogeneity (P Ͻ0.0001). The original table of Collier and colleagues contained an error. 10 Therefore, we used the corrected data of Collier. 7 There seems to be no methodological framework to combine the results of family-based association studies with those from case-control association studies. Thus, we are unable to include the findings of Hinney and colleagues 2 who performed a family-based association study and did not detect linkage and association between the −1438A/G promoter polymorphism and AN. Table 1 shows that both genotype and allele frequencies vary substantially between the individual studies resulting in dissimilar OR. For instance, the frequency for controls being homozygous for the A allele ranges from 8.70% 5 to 20.00%.
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The meta-analysis combining the studies using the data shown in Table 1 yields similar results for the allelic and the genotypic OR. Our meta-analysis did not detect association between the −1438A/G promoter polymorphism and AN (both nominal P Ͼ0.11). Possible explanations for the inconsistencies between study results are many-fold as discussed eg by Paterson. 11 These include genetic heterogeneity or ethnic admixture. 2 The latter can be circumvented by family-based association studies. 2 potential control group recruits which met symptom requirements for ADHD. It has been my experience as a reader of ADHD research that ADHD and control participants tend to be recruited differently (clinical vs non-clinical populations) and that controls tend to be excluded for exhibiting comorbid conditions (ie, conduct disorder) commonly diagnosed in the ADHD participants.
Recruiting the experimental and control groups from different populations may reveal group differences in repeat frequencies unrelated to participant status which may result in both false-positive and false negative results. 3 Secondly, though Castellanos et al's 1 report of a 71% comorbidity rate is quite high, there does tend to be a higher rate of comorbidity in clinicreferred than in non-referred children diagnosed with ADHD. 4 Since it has been put forward that comorbidity may moderate the phenotypic expression of ADHD, 5, 6 it may be necessary to account for the effects of comorbidity on the expression of ADHD when doing genetic research.
I postulate that the best way to avoid the statistical errors associated with the sampling biases listed above is, instead of recruiting on the basis of phenotype and testing for genotype, we should recruit on the basis of genotype and test for phenotype. Considering the present interest in the relationship between the DRD4 and ADHD 7 and the suggestion that the DRD2 is a major moderator of ADHD, 4 I propose that we employ a 5 × 3 factorial design using only those individuals with the 2,2, 2,4, 4,4, 4,7 and 7,7 repeats of the DRD4 gene and the A1,A1, A1,A2 and A2,A2 alleles of the DRD2 gene. The proposed design will not only show the independent effect of each gene on the expression of ADHD and various comorbid conditions (as well as possible interactions), but will also provide a large group of (DRD4) 4,4 repeat, (DRD2) A2,A2 alleles participants that may be used to test the influence of other proposed ADHD genes, such as Cook et al's 3 DAT1. 
V Lavallee

Waldman and Rowe reply
SIR -In her recent letter to Molecular Psychiatry, Ms Lavallee raises a number of interesting issues in genetic research on ADHD. In this comment, we focus on three of these issues regarding the sampling of participants in molecular genetic studies of ADHD. Specifically, we address the issues of choice of controls, the impact of overlapping diagnostic conditions, and the viability of recruiting participants based on genotype vs phenotype. Ms Lavallee raises the appropriate concern that ADHD and comparison groups recruited from different populations might differ in allele frequencies for reasons other than linkage between the disorder and the genetic marker. Although careful matching of cases and controls may overcome this problem to a degree, many potential sources of population stratification exist, some heretofore unknown, that could lead to associations that are not due to the casual effects of the gene. In order to counteract this problem, a number of recent molecular genetic studies of ADHD [1] [2] [3] [4] [5] have used a within-family statistical procedure, the Transmission Disequilibrium Test (TDT), 6 that protects against the biasing effects of population stratification. The TDT contrasts the transmission of high-risk vs low-risk alleles from heterozygous parents to their affected children. Use of the TDT should eliminate any population stratification biases incurred in the comparison of ADHD cases with controls, which may be drawn from populations with characteristics that differ in important ways.
